GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » Equity-to-Asset

Accelerate Diagnostics (Accelerate Diagnostics) Equity-to-Asset : -0.63 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Accelerate Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-19.89 Mil. Accelerate Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was $31.37 Mil. Therefore, Accelerate Diagnostics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.63.

The historical rank and industry rank for Accelerate Diagnostics's Equity-to-Asset or its related term are showing as below:

AXDX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.67   Med: 0.13   Max: 0.96
Current: -0.63

During the past 13 years, the highest Equity to Asset Ratio of Accelerate Diagnostics was 0.96. The lowest was -0.67. And the median was 0.13.

AXDX's Equity-to-Asset is ranked worse than
95.29% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs AXDX: -0.63

Accelerate Diagnostics Equity-to-Asset Historical Data

The historical data trend for Accelerate Diagnostics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Equity-to-Asset Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.67 -0.42 -0.34 -0.63

Accelerate Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.76 -0.78 -0.89 -0.63

Competitive Comparison of Accelerate Diagnostics's Equity-to-Asset

For the Medical Devices subindustry, Accelerate Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Equity-to-Asset falls into.



Accelerate Diagnostics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Accelerate Diagnostics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-19.888/31.366
=-0.63

Accelerate Diagnostics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-19.888/31.366
=-0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerate Diagnostics  (NAS:AXDX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Accelerate Diagnostics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (Accelerate Diagnostics) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Executives
David Patience officer: Chief Financial Officer C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Jack Phillips director, officer: PRESIDENT AND CEO 11731 YALE DR, CARMEL IN 46032
Larry Michael Mertz officer: Chief Technology Officer 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Marran H. Ogilvie director 599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan director C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black director 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling officer: CFO 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price officer: SVP & HEAD OF COM OPS AMERICAS 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris director 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Mark C Miller director C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Ten Brink Frank Jm director C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Louise Francesconi director 870 WINTER STREET, WALTHAM MA 02451